VEEV:NYE-Veeva Systems Inc. Class A (USD)

EQUITY | Health Information Services | New York Stock Exchange

Last Closing

USD 214.01

Change

0.00 (0.00)%

Market Cap

USD 6.08B

Volume

0.67M

Analyst Target

USD 304.05
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Veeva Systems Inc is a provider of industry-specific, cloud-based software solutions for the life sciences industry.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

N/A

USD 10.78B
DOCS Doximity Inc

N/A

USD 10.37B
WEAV Weave Communications Inc

N/A

USD 1.13B
AMWL American Well Corp

N/A

USD 0.15B
MPLN MultiPlan Corporation

N/A

USD 0.12B
OWLT Owlet Inc

N/A

USD 0.08B
PHR Phreesia Inc

N/A

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

N/A

N/A
TDOC Teladoc Inc

N/A

N/A

ETFs Containing VEEV

EKG First Trust Nasdaq Lux Di.. 8.02 % 0.00 %

N/A

USD 2.66M
CURG:LSE VanEck Genomics and Healt.. 6.96 % 0.00 %

N/A

USD 5.35M
CURE:XETRA VanEck Genomics and Healt.. 5.89 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.82 % 0.00 %

N/A

N/A
FDOC:LSE Fidelity Digital Health U.. 4.58 % 0.00 %

N/A

USD 3.18M
FDHT Fidelity Covington Trust .. 4.28 % 0.00 %

N/A

USD 8.02M
SGLC Rbb Fund Inc. - Sgi U.S L.. 2.75 % 0.00 %

N/A

USD 0.10B
MOAT:SW VanEck Morningstar US Sus.. 2.51 % 0.00 %

N/A

N/A
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.43 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.43 % 0.00 %

N/A

N/A
VVGM:XETRA VanEck Morningstar Global.. 2.09 % 0.00 %

N/A

USD 0.07B
JMID Janus Henderson Mid Cap G.. 1.97 % 0.00 %

N/A

USD 0.02B
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
EASI 0.00 % 0.75 %

N/A

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

N/A

N/A
GMVM:XETRA VanEck Morningstar US Sus.. 0.00 % 0.00 %

N/A

USD 0.53B
VMOM:XETRA 0.00 % 0.00 %

N/A

N/A
LCG Sterling Capital Focus Eq.. 0.00 % 0.00 %

N/A

USD 0.04B
MOGB:LSE VanEck Morningstar US Sus.. 0.00 % 0.00 %

N/A

USD 0.44B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.16% 70% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.16% 70% C- 57% F
Trailing 12 Months  
Capital Gain 11.16% 70% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.16% 70% C- 57% F
Trailing 5 Years  
Capital Gain 51.88% 100% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.88% 100% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 4.31% 64% D 49% F
Dividend Return 4.31% 64% D 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.67% 91% A- 31% F
Risk Adjusted Return 12.79% 73% C 28% F
Market Capitalization 6.08B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 109.90 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector